0
Editorials |

Think of HIT When Thrombosis Follows Heparin

Theodore E. Warkentin, MD
Author and Funding Information

Affiliations: Hamilton, ON, Canada
 ,  Dr. Warkentin is Professor, Department of Pathology and Molecular Medicine, and Department of Medicine, McMaster University. He is also Associate Head of Transfusion Medicine, Hamilton Regional Laboratory Medicine Program, and Hematologist, Hamilton Health Sciences (Hamilton General Site).

Correspondence to: Theodore E. Warkentin, MD, Room 1-180A, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences (Hamilton General Site), 237 Barton St E, Hamilton, ON, L8L 2X2, Canada; e-mail: twarken@mcmaster.ca



Chest. 2006;130(3):631-632. doi:10.1378/chest.130.3.631
Text Size: A A A
Published online

Extract

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are the most common thrombotic complications of heparin-induced thrombocytopenia (HIT).1 Appropriately, review articles discussing HIT diagnosis and management typically indicate that the possibility of HIT should be considered when a manifestation of venous thromboembolism (VTE) either during or soon after antithrombotic therapy or prophylaxis with heparin develops in a patient.23 However, the converse is not necessarily true. Reviews of VTE management sometimes do not mention that a diagnosis of HIT should be considered during a diagnostic evaluation of VTE.45 In part, this “disconnect” arises because there is little information quantifying the risk of HIT in a patient in whom VTE develops during or soon after receiving unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH).

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Heparin for the treatment of thrombosis in neonates. Cochrane Database Syst Rev Published online Nov 07, 2016;
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543